Drug-induced injury of the gastrointestinal tract

Surgical Pathology Clinics

Volumn 3, Issue 2, 2010, Pages 361-393

  Gordon, Ilyssa O ^a   Konda, Vani ^a   Noffsinger, Amy E ^b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Chemotherapeutic agents; Drug induced injury; Gastrointestinal tract; Nonsteroidal antiinflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; AMPHETAMINE; ANESTHETIC AGENT; ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; COLCHICINE; CORTICOSTEROID; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DIURETIC AGENT; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; INTERFERON; IRON; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; OPIATE AGONIST; ORAL CONTRACEPTIVE AGENT; PACLITAXEL; POTASSIUM CHLORIDE; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ALCOHOL CONSUMPTION; ALLERGY; ANGIODYSPLASIA; ANOREXIA; APOPTOSIS; ARTHRALGIA; AUTOIMMUNE PANARTERITIS; BARRETT ESOPHAGUS; BILE REFLUX; BLEEDING; BLOOD FLOW; BLOOD VESSEL HAMARTOMA; BLOODY DIARRHEA; CANDIDIASIS; CARCINOMA; CELL CYCLE ARREST; CELL DAMAGE; CELL DEATH; CELL POLARITY; CELL REGENERATION; CELLULAR ATYPIA; CHEMICAL INJURY; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; COLON DIVERTICULOSIS; COLON HEMORRHAGE; COLON OBSTRUCTION; COLON PERFORATION; COLONOSCOPY; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTINUOUS INFUSION; CRYPTITIS; CYSTIC FIBROSIS; CYTOMEGALOVIRUS INFECTION; CYTOTOXICITY; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIGESTIVE SYSTEM PERFORATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG TARGETING; DUODENITIS; DUODENUM ULCER; DYSPEPSIA; DYSPHAGIA; EDEMA; ENDOTOXEMIA; ENTERITIS; ENTEROCOLITIS; ENZYME ACTIVITY; EOSINOPHILIA; EOSINOPHILIC GASTROENTERITIS; EPITHELIAL APOPTOSIS; EPITHELIUM CELL; ERYTHEMA; ESOPHAGITIS; ESOPHAGUS; ESOPHAGUS INJURY; ESOPHAGUS STRICTURE; ESOPHAGUS ULCER; FEVER; FIBRINOLYSIS; GANGRENE; GASTRITIS; GASTRODUODENAL MUCOSAL HYPEREMIA; GASTROENTERITIS; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; GERIATRIC PATIENT; GLANDULAR ATYPIA; GRAFT VERSUS HOST REACTION; GRANULATION TISSUE; GROWTH DISORDER; HAMARTOMA; HEARTBURN; HELICOBACTER INFECTION; HEMOLYTIC UREMIC SYNDROME; HEMORRHAGIC GASTROENTERITIS; HERPES SIMPLEX; HIATUS HERNIA; HISTOPATHOLOGY; HUMAN; HYPEREMIA; ILEUM DYSFUNCTION; ILEUS; IMMUNOSUPPRESSIVE TREATMENT; INBORN ERROR OF METABOLISM; INFECTIOUS ENTEROCOLITIS; INFLAMMATORY INFILTRATE; INJURY; INTESTINE HEMATOMA; INTESTINE ISCHEMIA; INTESTINE RESECTION; INTESTINE ULCER; INTRAEPITHELIAL LYMPHOCYTOSIS; IRON DEFICIENCY ANEMIA; ISCHEMIA; ISCHEMIC COLITIS; KARYORRHEXIS; KAYEXALATE SORBITOL ENEMA INJURY; LACTOSE INTOLERANCE; LARGE INTESTINE; LEUKOCYTOSIS; LOWER ESOPHAGUS SPHINCTER; LYMPHOCYTOSIS; LYMPHOPLASMACYTIC CELL; MALABSORPTION; MALLORY WEISS SYNDROME; MEGALOBLASTIC ANEMIA; MITOSIS; MUCOSA INFLAMMATION; MUCOSAL DIAPHRAGM DISEASE; MUCOSAL EOSINOPHILIA; MUCOSAL INFECTION; MYCOSIS; NAUSEA; NECROTIZING COLITIS; NEOPLASM; NERVE INJURY; NEUTROPENIC ENTEROCOLITIS; NUCLEAR PYKNOSIS; NUTRITIONAL STATUS; OPPORTUNISTIC INFECTION; PANCREATIC ENZYME INSUFFICIENCY; PARASITOSIS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PEPTIC DUODENITIS; PEPTIC ULCER; PETECHIA; PLASMA CELL; PLEOMORPHISM; POLYARTERITIS NODOSA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEPLETION; PSEUDOMEMBRANOUS COLITIS; QUALITY OF LIFE; RADIATION; RECTUM HEMORRHAGE; REFLUX ESOPHAGITIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEPSIS; SHOCK; SIDE EFFECT; SMALL INTESTINE; STEATORRHEA; STOMACH; STOMACH DISEASE; STOMACH EROSION; STOMACH HEMORRHAGE; STOMACH MUCOSA; STOMACH PERFORATION; STOMACH ULCER; STOMATITIS; SUPPOSITORY; SYSTEMIC DISEASE; TENESMUS; THROMBOSIS; TOBACCO DEPENDENCE; TREATMENT WITHDRAWAL; TUMOR CELL; ULCER; UPPER GASTROINTESTINAL BLEEDING; VASCULITIS; VASOSPASM; VIRUS INFECTION; VITAMIN SUPPLEMENTATION; VOMITING;

EID: 77955643118     PISSN: 18759181     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.path.2010.05.007     Document Type: Review

References (138)

1. Kikendall J.W., Friedman A.C., Oyewole M.A., et al. Pill-induced esophageal injury. Case reports and review of the medical literature. Dig Dis Sci 1983, 28(2):174-182.
2. Stoschus B., Allescher H.D. Drug-induced dysphagia. Dysphagia 1993, 8(2):154-159.
3. Gabriel S.E., Jaakkimainen L., Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991, 115(10):787-796.
4. Piper J.M., Ray W.A., Daugherty J.R., et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991, 114(9):735-740.
5. Ratnaike R.N., Jones T.E. Mechanisms of drug-induced diarrhoea in the elderly. Drugs Aging 1998, 13(3):245-253.
6. Chassany O., Michaux A., Bergmann J.F. Drug-induced diarrhoea. Drug Saf 2000, 22(1):53-72.
7. Eckardt V.F., Kanzler G., Remmele W. Anorectal ergotism: another cause of solitary rectal ulcers. Gastroenterology 1986, 91(5):1123-1127.
8. Walt R., Katschinski B., Logan R., et al. Rising frequency of ulcer perforation in elderly people in the United Kingdom. Lancet 1986, 1(8479):489-492.
9. Griffin M.R., Piper J.M., Daugherty J.R., et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991, 114(4):257-263.
10. Fries J.F., Williams C.A., Bloch D.A., et al. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991, 91(3):213-222.
11. Naesdal J., Brown K. NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options. Drug Saf 2006, 29(2):119-132.
12. Allison M.C., Howatson A.G., Torrance C.J., et al. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 1992, 327(11):749-754.
13. Papatheodoridis G.V., Sougioultzis S., Archimandritis A.J. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. Clin Gastroenterol Hepatol 2006, 4(2):130-142.
14. Laine L., Bombardier C., Hawkey C.J., et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002, 123(4):1006-1012.
15. Hawkey C.J., Naesdal J., Wilson I., et al. Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs. Gut 2002, 51(3):336-343.
16. Carson J.L., Strom B.L., Morse M.L., et al. The relative gastrointestinal toxicity of the nonsteroidal anti-inflammatory drugs. Arch Intern Med 1987, 147(6):1054-1059.
17. Shorr R.I., Ray W.A., Daugherty J.R., et al. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993, 153(14):1665-1670.
18. Huang J.Q., Sridhar S., Hunt R.H. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002, 359(9300):14-22.
19. Langman M.J., Weil J., Wainwright P., et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994, 343(8905):1075-1078.
20. Garcia Rodriguez L.A., Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994, 343(8900):769-772.
21. Richy F., Bruyere O., Ethgen O., et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 2004, 63(7):759-766.
22. Bjarnason I., Macpherson A.J. Intestinal toxicity of non-steroidal anti-inflammatory drugs. Pharmacol Ther 1994, 62(1-2):145-157.
23. Davies N.M., Saleh J.Y., Skjodt N.M. Detection and prevention of NSAID-induced enteropathy. J Pharm Pharm Sci 2000, 3(1):137-155.
24. Peura D.A. Prevention of nonsteroidal anti-inflammatory drug-associated gastrointestinal symptoms and ulcer complications. Am J Med 2004, 117(Suppl 5A):63S-71S.
25. Wolfe F., Hawley D.J. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients. J Rheumatol 2000, 27(7):1668-1673.
26. Larkai E.N., Smith J.L., Lidsky M.D., et al. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987, 82(11):1153-1158.
27. Fortun P.J., Hawkey C.J. Nonsteroidal antiinflammatory drugs and the small intestine. Curr Opin Gastroenterol 2007, 23(2):134-141.
28. Bjarnason I., Hayllar J., MacPherson A.J., et al. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993, 104(6):1832-1847.
29. Kaufmann H.J., Taubin H.L. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 1987, 107(4):513-516.
30. Laine L., Connors L.G., Reicin A., et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003, 124(2):288-292.
31. Gibson G.R., Whitacre E.B., Ricotti C.A. Colitis induced by nonsteroidal anti-inflammatory drugs. Report of four cases and review of the literature. Arch Intern Med 1992, 152(3):625-632.
32. Gizzi G., Villani V., Brandi G., et al. Ano-rectal lesions in patients taking suppositories containing non-steroidal anti-inflammatory drugs (NSAID). Endoscopy 1990, 22(3):146-148.
33. Vane J.R., Botting R.M. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998, 104(3A):2S-8S. [discussion: 21S-22S].
34. Mitchell J.A., Akarasereenont P., Thiemermann C., et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A 1993, 90(24):11693-11697.
35. Donnelly M.T., Hawkey C.J. Review article: COX-II inhibitors-a new generation of safer NSAIDs?. Aliment Pharmacol Ther 1997, 11(2):227-236.
36. Scarpignato C. Nonsteroidal anti-inflammatory drugs: how do they damage gastroduodenal mucosa?. Dig Dis 1995, 13(Suppl 1):9-39.
37. Hawkey C.J. Non-steroidal anti-inflammatory drug gastropathy: causes and treatment. Scand J Gastroenterol Suppl 1996, 220:124-127.
38. Cagossi M., Salgarello M., Patrignani P., et al. Effects of various prostaglandin synthesis inhibitors on the tone of the lower oesophageal sphincter in man. Eur J Clin Pharmacol 1992, 43(3):303-305.
39. Sopena F., Lanas A., Sainz R. Esophageal motility and intraesophageal pH patterns in patients with esophagitis and chronic nonsteroidal anti-inflammatory drug use. J Clin Gastroenterol 1998, 27(4):316-320.
40. Bigard M.A., Pelletier A.L. Gastroenterol Clin Biol 2004, 28(Spec No 3):C58-C61. [in French].
41. Atchison C.R., West A.B., Balakumaran A., et al. Drug enterocyte adducts: possible causal factor for diclofenac enteropathy in rats. Gastroenterology 2000, 119(6):1537-1547.
42. Aalykke C., Lauritsen J.M., Hallas J., et al. Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a case-control study. Gastroenterology 1999, 116(6):1305-1309.
43. Maiden L., Thjodleifsson B., Theodors A., et al. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005, 128(5):1172-1178.
44. Hayashi Y., Yamamoto H., Kita H., et al. Non-steroidal anti-inflammatory drug-induced small bowel injuries identified by double-balloon endoscopy. World J Gastroenterol 2005, 11(31):4861-4864.
45. Lang J., Price A.B., Levi A.J., et al. Diaphragm disease: pathology of disease of the small intestine induced by non-steroidal anti-inflammatory drugs. J Clin Pathol 1988, 41(5):516-526.
46. Zalev A.H., Gardiner G.W., Warren R.E. NSAID injury to the small intestine. Abdom Imaging 1998, 23(1):40-44.
47. Going J.J., Canvin J., Sturrock R. Possible precursor of diaphragm disease in the small intestine. Lancet 1993, 341(8845):638-639.
48. Robinson M.H., Wheatley T., Leach I.H. Nonsteroidal antiinflammatory drug-induced colonic stricture. An unusual cause of large bowel obstruction and perforation. Dig Dis Sci 1995, 40(2):315-319.
49. Konturek S.J., Brzozowski T., Stachura J., et al. Role of gastric blood flow, neutrophil infiltration, and mucosal cell proliferation in gastric adaptation to aspirin in the rat. Gut 1994, 35(9):1189-1196.
50. Lee F.D. Importance of apoptosis in the histopathology of drug related lesions in the large intestine. J Clin Pathol 1993, 46(2):118-122.
51. Price A.B. Pathology of drug-associated gastrointestinal disease. Br J Clin Pharmacol 2003, 56(5):477-482.
52. Baert F., Hart J., Blackstone M.O. A case of diclofenac-induced colitis with focal granulomatous change. Am J Gastroenterol 1995, 90(10):1871-1873.
53. El-Zimaity H.M., Genta R.M., Graham D.Y. Histological features do not define NSAID-induced gastritis. Hum Pathol 1996, 27(12):1348-1354.
54. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000, 343(21):1520-1528. 1522 p following 1528.
55. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000, 284(10):1247-1255.
56. Kelly J.P., Kaufman D.W., Jurgelon J.M., et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996, 348(9039):1413-1416.
57. Cullen D., Bardhan K.D., Eisner M., et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther 1998, 12(2):135-140.
58. Singh G., Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl 1999, 56:18-24.
59. Ament P.W., Childers R.S. Prophylaxis and treatment of NSAID-induced gastropathy. Am Fam Physician 1997, 55(4):1323-1326. 1331-1322.
60. Wolfe M.M., Lichtenstein D.R., Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999, 340(24):1888-1899.
61. Buroker T.R., O'Connell M.J., Wieand H.S., et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994, 12(1):14-20.
62. Parnes H.L., Fung E., Schiffer C.A. Chemotherapy-induced lactose intolerance in adults. Cancer 1994, 74(5):1629-1633.
63. Liaw C.C., Huang J.S., Wang H.M., et al. Spontaneous gastroduodenal perforation in patients with cancer receiving chemotherapy and steroids. Report of four cases combining 5-fluorouracil infusion and cisplatin with antiemetics dexamethasone. Cancer 1993, 72(4):1382-1385.
64. Atherton L.D., Leib E.S., Kaye M.D. Toxic megacolon associated with methotrexate therapy. Gastroenterology 1984, 86(6):1583-1588.
65. Slavin R.E., Dias M.A., Saral R. Cytosine arabinoside induced gastrointestinal toxic alterations in sequential chemotherapeutic protocols: a clinical-pathologic study of 33 patients. Cancer 1978, 42(4):1747-1759.
66. Rose P.G., Piver M.S. Intestinal perforation secondary to paclitaxel. Gynecol Oncol 1995, 57(2):270-272.
67. Ferrero J.M., Francois E., Frenay M., et al. Presse Med 1993, 22(13):638. [in French].
68. Petras R.E., Hart W.R., Bukowski R.M. Gastric epithelial atypia associated with hepatic arterial infusion chemotherapy. Its distinction from early gastric carcinoma. Cancer 1985, 56(4):745-750.
69. Doria M.I., Doria L.K., Faintuch J., et al. Gastric mucosal injury after hepatic arterial infusion chemotherapy with floxuridine. A clinical and pathologic study. Cancer 1994, 73(8):2042-2047.
70. Trier J.S. Morphologic alterations induced by methotrexate in the mucosa of human proximal intestine. I. Serial observations by light microscopy. Gastroenterology 1962, 42:295-305.
71. Trier J.S. Morphologic alterations induced by methotrexate in the mucosa of human proximal intestine. II. Electron microscopic observations. Gastroenterology 1962, 43:407-424.
72. Lewis J.H. Gastrointestinal injury due to medicinal agents. Am J Gastroenterol 1986, 81(9):819-834.
73. Oble D.A., Mino-Kenudson M., Goldsmith J., et al. Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. Am J Surg Pathol 2008, 32(8):1130-1137.
74. Floch M.H., Hellman L. The effect of five-fluorouracil on rectal mucosa. Gastroenterology 1965, 48:430-437.
75. Milles S., Muggia A., Spiro H. Colonic histologic changes induced by 5-fluorouracil. Gastroenterology 1962, 43:391-399.
76. Sandmeier D., Chaubert P., Bouzourene H. Irinotecan-induced colitis. Int J Surg Pathol 2005, 13(2):215-218.
77. Boley S.J., Brandt L.J., Veith F.J. Ischemic disorders of the intestines. Curr Probl Surg 1978, 15(4):1-85.
78. Tedesco F.J., Volpicelli N.A., Moore F.S. Estrogen- and progesterone-associated colitis: a disorder with clinical and endoscopic features mimicking Crohn's colitis. Gastrointest Endosc 1982, 28(4):247-249.
79. Friedel D., Thomas R., Fisher R.S. Ischemic colitis during treatment with alosetron. Gastroenterology 2001, 120(2):557-560.
80. Sparano J.A., Dutcher J.P., Kaleya R., et al. Colonic ischemia complicating immunotherapy with interleukin-2 and interferon-alpha. Cancer 1991, 68(7):1538-1544.
81. de Silva P., Deb S., Drummond R.D., et al. A fatal case of ischaemic colitis following long-term use of neuroleptic medication. J Intellect Disabil Res 1992, 36(Pt 4):371-375.
82. Shpilberg O., Ehrenfeld M., Abramowich D., et al. Ergotamine-induced solitary rectal ulcer. Postgrad Med J 1990, 66(776):483-485.
83. Voora D., Vijayan A. Mesenteric vein thrombosis associated with intravaginal contraceptives: a case report and review of the literature. J Thromb Thrombolysis 2003, 15(2):105-108.
84. Hassan H.A. Oral contraceptive-induced mesenteric venous thrombosis with resultant intestinal ischemia. J Clin Gastroenterol 1999, 29(1):90-95.
85. Hoyle M., Kennedy A., Prior A.L., et al. Small bowel ischaemia and infarction in young women taking oral contraceptives and progestational agents. Br J Surg 1977, 64(8):533-537.
86. Tanis B.C., Rosendaal F.R. Venous and arterial thrombosis during oral contraceptive use: risks and risk factors. Semin Vasc Med 2003, 3(1):69-84.
87. Abel M.E., Russell T.R. Ischemic colitis. Comparison of surgical and nonoperative management. Dis Colon Rectum 1983, 26(2):113-115.
88. Watson M.R., Mark J.B. Ulceration of the small intestine. Relation to enteric-coated potassium. Am J Surg 1966, 112(3):421-425.
89. Brewer A.R., Smyrk T.C., Bailey R.T., et al. Drug-induced esophageal injury. Histopathological study in a rabbit model. Dig Dis Sci 1990, 35(10):1205-1210.
90. Biedrzycki O.J., Arnaout A., Coppen M.J., et al. Isolated intramucosal goblet cells in subacute ischaemic enteritis: mimicry of signet ring cell carcinoma. Histopathology 2005, 46(4):460-462.
91. Centers for Disease Control and Prevention (CDC) Hypertrophic pyloric stenosis in infants following pertussis prophylaxis with erythromycin-Knoxville, Tennessee, 1999. MMWR Morb Mortal Wkly Rep 1999, 48(49):1117-1120.
92. Navarro H., Arruebo M.P., Alcalde A.I., et al. Effect of erythromycin on d-galactose absorption and sucrase activity in rabbit jejunum. Can J Physiol Pharmacol 1993, 71(3-4):191-194.
93. Cappell M.S., Simon T. Colonic toxicity of administered medications and chemicals. Am J Gastroenterol 1993, 88(10):1684-1699.
94. Banisaeed N., Truding R.M., Chang C.H. Tetracycline-induced spongiotic esophagitis: a new endoscopic and histopathologic finding. Gastrointest Endosc 2003, 58(2):292-294.
95. Conn H.O., Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med 1994, 236(6):619-632.
96. Messer J., Reitman D., Sacks H.S., et al. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 1983, 309(1):21-24.
97. Delaney J.P., Michel H.M., Bonsack M.E., et al. Adrenal corticosteroids cause gastrin cell hyperplasia. Gastroenterology 1979, 76(5 Pt 1):913-916.
98. Crane P.W., Clark C., Sowter C., et al. Cyclosporine toxicity in the small intestine. Transplant Proc 1990, 22(6):2432.
99. Papadimitriou J.C., Cangro C.B., Lustberg A., et al. Histologic features of mycophenolate mofetil-related colitis: a graft-versus-host disease-like pattern. Int J Surg Pathol 2003, 11(4):295-302.
100. Gabe S.M., Bjarnason I., Tolou-Ghamari Z., et al. The effect of tacrolimus (FK506) on intestinal barrier function and cellular energy production in humans. Gastroenterology 1998, 115(1):67-74.
101. Maes B.D., Dalle I., Geboes K., et al. Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. Transplantation 2003, 75(5):665-672.
102. Fisher A., Schwartz M., Mor E., et al. Gastrointestinal toxicity associated with FK 506 in liver transplant recipients. Transplant Proc 1994, 26(6):3106-3107.
103. Akioka K., Okamoto M., Nakamura K., et al. Abdominal pain is a critical complication of mycophenolate mofetil in renal transplant recipients. Transplant Proc 2003, 35(1):300-301.
104. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 2001, 24(9):645-663.
105. Roy M.J., Walsh T.J. Histopathologic and immunohistochemical changes in gut-associated lymphoid tissues after treatment of rabbits with dexamethasone. Lab Invest 1992, 66(4):437-443.
106. ReMine S.G., McIlrath D.C. Bowel perforation in steroid-treated patients. Ann Surg 1980, 192(4):581-586.
107. O'Neil E.A., Chwals W.J., O'Shea M.D., et al. Dexamethasone treatment during ventilator dependency: possible life threatening gastrointestinal complications. Arch Dis Child 1992, 67(1 Spec No):10-11.
108. Abraham S.C., Bhagavan B.S., Lee L.A., et al. Upper gastrointestinal tract injury in patients receiving kayexalate (sodium polystyrene sulfonate) in sorbitol: clinical, endoscopic, and histopathologic findings. Am J Surg Pathol 2001, 25(5):637-644.
109. Roy-Chaudhury P., Meisels I.S., Freedman S., et al. Combined gastric and ileocecal toxicity (serpiginous ulcers) after oral kayexalate in sorbital therapy. Am J Kidney Dis 1997, 30(1):120-122.
110. Chatelain D., Brevet M., Manaouil D., et al. Rectal stenosis caused by foreign body reaction to sodium polystyrene sulfonate crystals (Kayexalate). Ann Diagn Pathol 2007, 11(3):217-219.
111. Gardiner G.W. Kayexalate (sodium polystyrene sulphonate) in sorbitol associated with intestinal necrosis in uremic patients. Can J Gastroenterol 1997, 11(7):573-577.
112. Rashid A., Hamilton S.R. Necrosis of the gastrointestinal tract in uremic patients as a result of sodium polystyrene sulfonate (Kayexalate) in sorbitol: an underrecognized condition. Am J Surg Pathol 1997, 21(1):60-69.
113. Rugolotto S., Gruber M., Solano P.D., et al. Necrotizing enterocolitis in a 850 gram infant receiving sorbitol-free sodium polystyrene sulfonate (Kayexalate): clinical and histopathologic findings. J Perinatol 2007, 27(4):247-249.
114. Venho V.M., Koivuniemi A. Effect of colchicine on drug absorption from the rat small intestine in situ and in vitro. Acta Pharmacol Toxicol (Copenh) 1978, 43(4):251-259.
115. Stemmermann G.N., Hayashi T. Colchicine intoxication. A reappraisal of its pathology based on a study of three fatal cases. Hum Pathol 1971, 2(2):321-332.
116. Hawkins C.F. Gastrointestinal lesions causing macrocytic anemia. Proc R Soc Med 1965, 58(9):717-721.
117. Iacobuzio-Donahue C.A., Lee E.L., Abraham S.C., et al. Colchicine toxicity: distinct morphologic findings in gastrointestinal biopsies. Am J Surg Pathol 2001, 25(8):1067-1073.
118. Al-Daraji W.I., Al-Mahmoud R.M., Ilyas M. Gastric changes following colchicine therapy in patients with FMF. Dig Dis Sci 2008, 53(8):2079-2082.
119. Smyth R.L., Ashby D., O'Hea U., et al. Fibrosing colonopathy in cystic fibrosis: results of a case-control study. Lancet 1995, 346(8985):1247-1251.
120. Smyth R.L., van Velzen D., Smyth A.R., et al. Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes. Lancet 1994, 343(8889):85-86.
121. Pawel B.R., de Chadarevian J.P., Franco M.E. The pathology of fibrosing colonopathy of cystic fibrosis: a study of 12 cases and review of the literature. Hum Pathol 1997, 28(4):395-399.
122. FitzSimmons S.C., Burkhart G.A., Borowitz D., et al. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med 1997, 336(18):1283-1289.
123. de Groen P.C., Lubbe D.F., Hirsch L.J., et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996, 335(14):1016-1021.
124. Aki S., Eskiyurt N., Akarirmak U., et al. Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis. Yonsei Med J 2003, 44(6):961-967.
125. Abraham S.C., Cruz-Correa M., Lee L.A., et al. Alendronate-associated esophageal injury: pathologic and endoscopic features. Mod Pathol 1999, 12(12):1152-1157.
126. Graham D.Y., Malaty H.M. Alendronate gastric ulcers. Aliment Pharmacol Ther 1999, 13(4):515-519.
127. Klinkenberg-Knol E.C., Nelis F., Dent J., et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000, 118(4):661-669.
128. Cats A., Schenk B.E., Bloemena E., et al. Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment. Hum Pathol 2000, 31(6):684-690.
129. Welch D.C., Wirth P.S., Goldenring J.R., et al. Gastric graft-versus-host disease revisited: does proton pump inhibitor therapy affect endoscopic gastric biopsy interpretation?. Am J Surg Pathol 2006, 30(4):444-449.
130. Krishnamurthy S., Dayal Y. Parietal cell protrusions in gastric ulcer disease. Hum Pathol 1997, 28(10):1126-1130.
131. Walker N.I., Bennett R.E., Axelsen R.A. Melanosis coli. A consequence of anthraquinone-induced apoptosis of colonic epithelial cells. Am J Pathol 1988, 131(3):465-476.
132. Benavides S.H., Morgante P.E., Monserrat A.J., et al. The pigment of melanosis coli: a lectin histochemical study. Gastrointest Endosc 1997, 46(2):131-138.
133. van Gorkom B.A., Karrenbeld A., van der Sluis T., et al. Apoptosis induction by sennoside laxatives in man; escape from a protective mechanism during chronic sennoside use?. J Pathol 2001, 194(4):493-499.
134. Xing J.H., Soffer E.E. Adverse effects of laxatives. Dis Colon Rectum 2001, 44(8):1201-1209.
135. Freeman H.J. "Melanosis" in the small and large intestine. World J Gastroenterol 2008, 14(27):4296-4299.
136. Smith B. Effect of irritant purgatives on the myenteric plexus in man and the mouse. Gut 1968, 9(2):139-143.
137. Pardi D.S., Tremaine W.J., Rothenberg H.J., et al. Melanosis coli in inflammatory bowel disease. J Clin Gastroenterol 1998, 26(3):167-170.
138. Byers R.J., Marsh P., Parkinson D., et al. Melanosis coli is associated with an increase in colonic epithelial apoptosis and not with laxative use. Histopathology 1997, 30(2):160-164.